READING UK, 25 FEB 2013 -- TranScrip Partners is delighted to announce that Richard Bax is the chairman of day one of Superbugs & Superdrugs a Focus on Antibacterials. This marks the 10th time Dr Bax will chair this meeting. Following his opening remarks, Dr Bax will present an update on current R&D and the regulatory environment covering topics such as big and little pharma activity and progress, a report on REACT, BSAC, IDSA, Barda FP7 EU and Innovative Medicines Initiative, a developer’s view on the EMA workshop on the development of new antibacterial medicines and prospects for the future.
This, the 15th Annual Superbugs and Superdrugs Conference, presented by SMi, will bring together industry leaders from contract organisations, pharma, biotechs, regulatory agencies and academia to discuss the latest developments in antibacterials and anti-infectives. This exciting conference will include the key topics of the EMA approach to regulating antimicrobials, developing partnerships, novel programmes for combating antibiotic resistance, synthesis techniques for novel inhibitors, immunization strategies for C. difficile infections, modern technologies for diagnostics and high-throughput screening processes for natural product-like molecules.
Conference Chairman Richard Bax has over 100 publications in peer reviewed journals including the BMJ, The Lancet and the New England Journal of Medicine. His published articles cover topics such as clinical trials, antibiotic resistance and prescribing, PK/PD predictors of outcome and the pharmaceutical industry.
Richard is a TranScrip expert in infectious diseases and has over 30 years of industry experience in clinical development programmes and regulatory submissions and has developed several antibiotics, antifungals, antivirals and vaccines.
Throughout his varied career, Richard has been a member of working parties of the BSAC, ESCMID, European Union Grant Committee, EFPIA, IFPMA, Wellcome Trust, Surgical Infection Society (US) and the working party of WHO on Bacterial Resistance as well as a consultant to the office of AIDS Research NIH US.
TranScrip Partners is a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management. TranScrip Partners are strategic thinkers that do, and doers who think strategically.
Working for more than 50 companies across 4 continents, TranScrip challenge the traditional CRO model by championing medicinal products and overcoming the hurdles encountered from translational medicine to successful registration and market access.
Contact:Leona Brunt Tel: +44 1189 637846 Fax: +44 1189 637497 Email: email@example.com Web: www.transcrip-partners.com Twitter: @TranScripPtnr
COO and Co-founder
Building 3, Chiswick Park
566 Chiswick High Road
London W4 5YA, United Kingdom
O: +44 20 8899 6821
M: +44 7850 446 520